Skip to main content

Abstract

Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of life and is perceived by patients as a major adverse effect of the treatment [1, 2]. Increased risk of CINV is associated with the type of chemotherapy administered (Table 1.1) and specific patient characteristics (Table 1.2) [3]. CINV can result in serious complications, such as weakness, weight loss, electrolyte imbalance, dehydration, or anorexia, and is associated with a variety of complications, including fractures, esophageal tears, decline in behavioral and mental status, and wound dehiscence [1]. Patients who are dehydrated, debilitated, or malnourished, as well as those who have an electrolyte imbalance or those who have recently undergone surgery or radiation therapy, are at greater risk of experiencing serious complications from CINV [1–3].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bloechl-Daum B, Deuson RR, Mavros P et al (2006) Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24:4472–4478

    Article  CAS  PubMed  Google Scholar 

  2. Cohen L, de Moor CA, Eisenberg P et al (2007) Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer 15(5):497–503

    Article  PubMed  Google Scholar 

  3. Navari RM (2009) Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments. Drugs 69:515–533

    Article  CAS  PubMed  Google Scholar 

  4. Navari RM (2010) Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer. Future Oncol 6:1074–1084

    Article  Google Scholar 

  5. Curran MP, Robinson DM (2009) Aprepitant: a review of its use in the prevention of nausea and vomiting. Drugs 69:1853–1858

    Article  CAS  PubMed  Google Scholar 

  6. Sankhala KK, Pandya DM, Sarantopoulos J et al (2009) Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant. Expert Opin Drug Metab Toxicol 12:1607–1614

    Article  Google Scholar 

  7. Navari RM (2015) Profile of netupitant/palonosetron fixed dose combination (NEPA) and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV). Drug Des Dev Ther 9:155–161

    Google Scholar 

  8. Navari RM (2015) Rolapitant for the treatment of chemotherapy induced nausea and vomiting. Expert Rev Anticancer Ther 15:1127–1133

    Article  CAS  PubMed  Google Scholar 

  9. Navari RM, Einhorn LH, Loehrer PJ et al (2007) A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting. Support Care Cancer 15:1285–1291

    Article  PubMed  Google Scholar 

  10. Tan L, Liu J, Liu X et al (2009) Clinical research of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. J Exp Clin Cancer Res 28:1–7

    Article  Google Scholar 

  11. Navari RM, Gray SE, Kerr AC (2011) Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 9:188–195

    Article  CAS  PubMed  Google Scholar 

  12. Navari RM (2012) Treatment of chemotherapy-induced nausea. Community Oncol 9:20–26

    Article  Google Scholar 

  13. Stern RM, Koch KL, Andrews PLR (eds) (2011) Nausea: mechanisms and management. Oxford University Press, New York

    Google Scholar 

  14. Roila F, Herrstedt J, Aapro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(5):232–243

    Article  Google Scholar 

  15. Basch E, Prestrud AA, Hesketh PJ et al (2011) Antiemetic American Society Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189–4198

    Article  PubMed  Google Scholar 

  16. NCCN Clinical Practice Guidelines in Oncology version 1 2015. Antiemesis. National Comprehensive Cancer Network (NCCN) [online]. Available from URL: http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf. Accessed Oct 2015

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Rudolph M. Navari MD, PhD, FACP .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Navari, R.M. (2016). Introduction. In: Navari, R. (eds) Management of Chemotherapy-Induced Nausea and Vomiting. Adis, Cham. https://doi.org/10.1007/978-3-319-27016-6_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-27016-6_1

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-27014-2

  • Online ISBN: 978-3-319-27016-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics